Binnopharm Group received sixteen marketing authorizations in the CIS markets in Q1 2024
27.03.2024
16 marketing authorizations were obtained by Binnopharm Group in Q1 2024 in the markets of 7 countries of the CIS+ region: Uzbekistan, Azerbaijan, Belarus, Armenia, Georgia, Kyrgyzstan and Moldova. Marketing authorizations were issued by regulatory authorities in accordance with local and Union requirements for the use of medicinal products on the territory of the above mentioned countries.
Marketing authorizations were obtained for the following drugs from the company's portfolio: VENARUS® (Moldova), Neobutin® (Belarus, Georgia), Nurofast® (Belarus, Kyrgyzstan), Urdoxa® (Georgia, Uzbekistan, Armenia), Bisoprolol-AKOS (Armenia), Clopidogrel-AKOS and Trimetazidin-AKOS MB (Azerbaijan), MOXONIDIN-ALIUM (Belarus), Meropenem (Kyrgyzstan).
Rustem Muratov, Chief Executive Officer of Binnopharm Group LLC: "Today Binnopharm Group is the leader in terms of export volumes among Russian pharmaceutical manufacturers, confirming patients' trust in Russian-made drugs in the CIS markets. Today our products are available in 13 countries around the world, and we have already opened representative offices in 8 countries, including China. We continue to open representative offices and introduce our products to new markets, for this purpose we are increasing the volume of registration of our drugs in foreign countries".
Marketing authorizations were obtained for the following drugs from the company's portfolio: VENARUS® (Moldova), Neobutin® (Belarus, Georgia), Nurofast® (Belarus, Kyrgyzstan), Urdoxa® (Georgia, Uzbekistan, Armenia), Bisoprolol-AKOS (Armenia), Clopidogrel-AKOS and Trimetazidin-AKOS MB (Azerbaijan), MOXONIDIN-ALIUM (Belarus), Meropenem (Kyrgyzstan).
Rustem Muratov, Chief Executive Officer of Binnopharm Group LLC: "Today Binnopharm Group is the leader in terms of export volumes among Russian pharmaceutical manufacturers, confirming patients' trust in Russian-made drugs in the CIS markets. Today our products are available in 13 countries around the world, and we have already opened representative offices in 8 countries, including China. We continue to open representative offices and introduce our products to new markets, for this purpose we are increasing the volume of registration of our drugs in foreign countries".
